Skip to main content
Shenogen signs cancer combo deal with Lee's Pharma
11/22/2017

Shenogen Pharma agreed to collaborate with Lee's Pharmaceutical to develop and market in China the combination of Lee's ZKAB001 and Shenogen's icaritin for the treatment of late-stage cancers. Shenogen is conducting a Phase III trial of icaritin in hepatocellular carcinoma patients.

Full Story: